Special Issue "Diabetes Mellitus: Promising Molecules, Drug Modification, Formulations, and Therapy"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 31 August 2023 | Viewed by 227

Special Issue Editor

Laboratory of Pharmacological Researches, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry (NIOCH SB RAS), Novosibirsk 630090, Russia
Interests: pharmaceutical development; host-guest complexes; medicinal and pharmaceutical chemistry; drug discovery; pharmacology; pharmaceutical formulation; toxicology; medicinal chemistry; biomedical materials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetes mellitus is a complex and heterogeneous disease that can affect people at different stages of life. This disease is characterized by an impairment of the carbohydrate, lipid, and protein metabolism. Among the three known types of diabetes mellitus, Type 2 diabetes mellitus (T2DM) is the most common; it is often referred to as an epidemic affecting the developed countries of the world and is a noticeable disorder that manifests in the structure of metabolic syndrome. Despite the availability of various therapeutic agents in modern medicine, maintaining adequate levels of glycemic control is still a challenge. It requires improvements in pharmacotherapy by means of agents with new mechanisms of action and/or making improvements to existing drugs by creating innovative delivery systems.

Thus, this Special Issue aims to collect articles that are devoted to the study of the pharmacological properties of chemical compounds that have new, not yet applicable in medicine, mechanisms of hypoglycemic action. It also welcomes papers that attend to the creation of delivery systems and to other modifications made to drugs that are already available on the pharmaceutical market.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:

  • New therapy targets for T2DM treatment;
  • Drug discovery and development for diabetes treatments;
  • T2DM’s complications treatment;
  • Drug delivery systems for diabetes treatments;
  • Pharmaceutical formulation design for diabetes treatments.

I look forward to receiving your contributions.

Dr. Mikhail V. Khvostov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • diabetes mellitus
  • drug discovery
  • antidiabetic drugs
  • drug delivery system
  • pharmaceutical formulation design

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Bornyl-Containing Derivatives of Benzyloxyphenylpropanoic Acid as FFAR1 Agonists: In Vitro and In Vivo Studies
Pharmaceutics 2023, 15(6), 1670; https://doi.org/10.3390/pharmaceutics15061670 (registering DOI) - 07 Jun 2023
Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide. Several classes of hypoglycemic drugs are used to treat it, but various side effects limit their clinical use. Consequently, the search for new anti-diabetic agents remains an urgent task [...] Read more.
Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide. Several classes of hypoglycemic drugs are used to treat it, but various side effects limit their clinical use. Consequently, the search for new anti-diabetic agents remains an urgent task for modern pharmacology. In this investigation, we examined the hypoglycemic effects of bornyl-containing benzyloxyphenylpropanoic acid derivatives (QS-528 and QS-619) in a diet-induced model of T2DM. Animals were given the tested compounds per os at a dose of 30 mg/kg for 4 weeks. At the end of the experiment, compound QS-619 demonstrated a hypoglycemic effect, while QS-528 showed hepatoprotection. In addition, we performed a number of in vitro and in vivo experiments to study the presumed mechanism of action of the tested agents. Compound QS-619 was determined to activate the free fatty acid receptor-1 (FFAR1) similarly to the reference agonist GW9508 and its structural analogue QS-528. Both agents also increased insulin and glucose-dependent insulinotropic polypeptide concentrations in CD-1 mice. Our results indicate that QS-619 and QS-528 are probably full FFAR1 agonists. Full article
Show Figures

Figure 1

Back to TopTop